Anxiety

Best MCAT Prep Course (2024): Blueprint Prep & Magoosh Reviewed by Better Business Advice

Retrieved on: 
Friday, March 1, 2024

Better Business Advice, a prominent online platform providing business and consumer guidance, has released a comprehensive assessment of the top MCAT prep courses for the year 2024.

Key Points: 
  • Better Business Advice, a prominent online platform providing business and consumer guidance, has released a comprehensive assessment of the top MCAT prep courses for the year 2024.
  • The review highlights two leading MCAT prep companies: Blueprint Prep and Magoosh , both providing remarkable resources developed by academic experts.
  • Selecting the best MCAT prep course is paramount for optimizing preparation and attaining one’s desired score on the exam.
  • Better Business Advice provides a comprehensive review comparing the best MCAT prep courses which can be helpful for medical students planning to take the MCAT.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

Retrieved on: 
Thursday, February 29, 2024

The compounds come from Enveric’s extensive library of over 1,000 novel molecules generated using the Company’s Psybrary™ platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI™).

Key Points: 
  • The compounds come from Enveric’s extensive library of over 1,000 novel molecules generated using the Company’s Psybrary™ platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI™).
  • The three term sheets contemplate that the undisclosed licensee would receive exclusive, royalty-bearing global licenses to develop and sublicense the assets, along with cash buyout options and future option rights to substantially related assets in the Enveric portfolio.
  • The licensee would assume responsibility for all future preclinical and clinical development for all human and/or animal pharmaceutical applications.
  • The compound classes under the term sheets come from two of the seven portfolios of preclinical molecules that Enveric recently unveiled as available for out-licensing .

JCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease Community

Retrieved on: 
Thursday, February 29, 2024

RDD activities aim to raise awareness of rare diseases and to improve the quality of life of individuals with rare and intractable diseases through better diagnoses and treatments.

Key Points: 
  • RDD activities aim to raise awareness of rare diseases and to improve the quality of life of individuals with rare and intractable diseases through better diagnoses and treatments.
  • JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) endorses the important mission of RDD and will advocate for RDD 2024 in Japan.
  • There are more than 6,000 rare diseases with an estimated 300 million individuals worldwide living with a rare disease.
  • Highlights of external awareness raising-activities for RDD:
    For JCR, RDD does not stop on the last day of February; it reminds us of our purpose every day to help raise awareness and generate change for the rare disease community worldwide.

MindMed Reports 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, February 28, 2024

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.
  • “2023 was a highly productive year for MindMed, which concluded with positive Phase 2b results for MM120 in the treatment of adult patients with GAD,” said Rob Barrow, Chief Executive Officer and Director of the Company.
  • As of December 31, 2023, MindMed had cash and cash equivalents totaling $99.7 million compared to $142.1 million as of December 31, 2022.
  • MindMed management will host a conference call at 8:00 AM EST today to provide a corporate update and review the Company’s 2023 financial results.

Ketamine Wellness Clinic of Orange County Announces Acquisition of Mind Space Ketamine Infusion Clinic

Retrieved on: 
Wednesday, February 28, 2024

Ketamine Wellness Clinic of Orange County, a leader in ketamine infusion therapy for mental health and wellness, has acquired Mind Space Ketamine Infusion Clinic ("Mind Space").

Key Points: 
  • Ketamine Wellness Clinic of Orange County, a leader in ketamine infusion therapy for mental health and wellness, has acquired Mind Space Ketamine Infusion Clinic ("Mind Space").
  • The pioneering services of Mind Space will be integrated into the operations of Ketamine Wellness Clinic of Orange County, consolidating resources to enhance and expand patient care in Laguna Beach and greater Orange County.
  • Both Ketamine Wellness Clinic of Orange County and Mind Space have been revered for their innovative approaches to treating persistent mood disorders with ketamine infusion therapy.
  • "We are thrilled to welcome the Mind Space patients and their families to our clinic," said Michael Bronson, M.D., President and CEO of Ketamine Wellness Clinic of Orange County.

Employee Turnover and Compensation Expectations are Key Challenges Facing Employers, Franklin Templeton’s Voice of the American Workplace Survey Finds

Retrieved on: 
Wednesday, February 28, 2024

In its fourth year, Franklin Templeton’s Voice of the American Workplace Survey found that 91 percent of employers experienced turnover rates exceeding 10 percent in 2023.

Key Points: 
  • In its fourth year, Franklin Templeton’s Voice of the American Workplace Survey found that 91 percent of employers experienced turnover rates exceeding 10 percent in 2023.
  • Furthermore, employee expectations, particularly regarding compensation, are on the rise, with 80 percent of employers struggling to meet demands for increased compensation.
  • This year's survey examined both employer and employee perspectives, emphasizing the crucial need for aligning expectations with available resources.
  • “Managing heightened employee expectations is one of the biggest challenges facing employers today,” said Jacque Reardon, Head of Client Marketing for Retirement, Insurance, 529 and Wealth Management for Franklin Templeton.

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Retrieved on: 
Tuesday, February 27, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.
  • The following presentations occurred at AAAAI 2024:
    Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Bob Geng, Allergy and Immunology, University of California, San Diego, California, United States (Poster Presentation)
    Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users
    Earlier on-demand treatment was associated with a shorter attack duration, regardless of LTP use
    Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers: Sandra Christiansen, University of California San Diego, La Jolla, CA, United States (Poster Presentation)
    The most common barriers to earlier treatment were uncertainty if attack was real, thinking the attack would be mild, and wanting to save treatment for a severe attack
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: James Wedner, Washington University School of Medicine, St Louis, MO, United States (Poster Presentation)
    Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
    The results of this study highlighted the association between delayed treatment and treatment-related anxiety, with a higher proportion of patients who delayed treatment experiencing moderate to extreme anxiety
    Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment: Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, United States (Poster Presentation)
    Anxiety associated with not being able to refill on-demand treatment quickly impacted treatment decisions, which contributed to treatment delay or resulted in non-treatment of HAE attacks
    Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks: Princess Ogbogu, Division of Pediatric Allergy, Immunology, and Rheumatology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States (Poster Presentation)
    The Impact of On-demand Treatment on Quality of Life of People with HAE: Paula Busse, Department of Medicine, Division of Clinical Immunology, Mount Sinai, New York, United States (Poster Presentation)
    Characterizing the Perspective of Patients With HAE on Prophylactic Treatment: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada (Poster Presentation)
    Only 35% of LTP patients always carried on-demand treatment when away from home, while 43% of prophylaxis patients cited avoiding potential triggers as a reason for not carrying on-demand treatment at all times
    Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack: Constance Katelaris, Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia (Poster Presentation)
    “The results of these surveys clearly conveyed the challenges faced by patients trying to manage their HAE attacks with injectable on-demand treatments.
  • The resulting non-compliance with treatment guidelines may lead to poor clinical outcomes, even among patients receiving LTP,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “We believe the efficacy and safety data from our phase 3 trial for sebetralstat show a potential path forward to address these persisting unmet needs.”

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Retrieved on: 
Friday, February 23, 2024

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount.
  • The patents and applications being sold disclose and claim the synergistic combination of cannabidiol and second therapeutic agents for the treatment of cancer.
  • The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe, and Japan, with patent applications pending in Canada, Israel, and Korea.
  • Enveric retains no ownership rights in the divested portfolio, any companies owned by, or to be formed by the recipients.

Smith Micro Announces New SafePath OS™ Solution Expanding its Focus on Family Safety

Retrieved on: 
Thursday, February 22, 2024

Smith Micro Software, Inc. (Nasdaq: SMSI) today introduced SafePath OS™, a new family safety solution to be built on the Android operating system, which focuses on digital safety for children and families while providing mobile network operators (MNOs) another way to offer a kids phone to their subscribers.

Key Points: 
  • Smith Micro Software, Inc. (Nasdaq: SMSI) today introduced SafePath OS™, a new family safety solution to be built on the Android operating system, which focuses on digital safety for children and families while providing mobile network operators (MNOs) another way to offer a kids phone to their subscribers.
  • Smith Micro will work with MNOs to package and promote a kids phone with Smith Micro’s powerful flagship SafePath® digital family safety software preinstalled and configured on one or more devices selected by the MNO.
  • A software-only solution, SafePath OS will expand Smith Micro’s reach from a subscription app-only solution to enabling MNOs to offer devices powered by SafePath OS.
  • SafePath OS will provide an option for MNOs to market and promote a safe and secure kids device pre-loaded with the SafePath OS and position MNOs to more fully compete with over-the-top family safety solutions.

Child Abuse Survivor Files Motion for Sanctions Against the State of Washington for Withholding Material Evidence in Previous Civil Case According to Dearie Law Group

Retrieved on: 
Monday, February 26, 2024

The 2013 recording was part of an interview by the Washington State Patrol (WSP) during its criminal investigation into the sexual abuse.

Key Points: 
  • The 2013 recording was part of an interview by the Washington State Patrol (WSP) during its criminal investigation into the sexual abuse.
  • “We are absolutely astounded with this on two levels,” said Raymond Dearie, an attorney with Dearie Law Group, P.S.
  • “First, the CPS investigator is defined by law as a mandatory reporter – had she done her job back in 2003, A.K.
  • During the trial, Dearie Law Group filed a motion seeking sanctions against the State and the DCYF for withholding Wicks’ recorded statement.